Loading...
XSTO
HNSA
Market cap301mUSD
Dec 05, Last price  
33.40SEK
1D
0.54%
1Q
8.58%
Jan 2017
-71.33%
IPO
312.86%
Name

Hansa Biopharma AB

Chart & Performance

D1W1MN
XSTO:HNSA chart
P/E
—
P/S
16.52
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.44%
Rev. gr., 5y
119.48%
Revenues
171m
+27.76%
103,6752,983,7594,448,1861,282,2192,618,8351,727,0174,716,0005,434,0002,579,0003,442,0003,358,0003,364,0006,098,00033,878,000154,525,000134,094,000171,316,000
Net income
-807m
L-2.94%
-2,558,185-15,812,150-18,843,239-24,572,021-16,466,035-17,561,999-29,042,000-66,266,000-111,129,000-176,660,000-247,974,000-360,009,000-420,853,000-548,282,000-611,134,000-831,720,000-807,243,000
CFO
-675m
L-10.69%
-15,576,021-13,792,299-18,093,957-27,139,111-20,633,032-14,865,322-23,623,000-57,799,000-94,563,000-150,105,000-204,560,000-334,775,000-290,274,000-481,168,000-502,733,000-755,654,000-674,884,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
URL
https://www.hansabiopharma.com/
IPO date
Oct 17, 2007
Employees
162
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT